The Committee discusses GlaxoSmithKline’s investigational new drug application (IND) 157775, for Dostarlimab-gxly for injection. The proposed indication (use) for this product is as a single agent for treatment of patients with locally advanced, treatment-naive mismatch repair deficiency/microsatellite instability-high rectal cancer in a meeting to be held on February 9 at 11 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK, Cytel enter three-year agreement to expand Solara deployment
- GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler
- GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development